Skip to main content
For Healthcare Professionals
home_banner

We passionately
improve health

Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
 

THERAPEUTIC AREA

Metabolic

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.

  1. Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)

Learn More
Metabolic

Cardiovascular Disease

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

  1. Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn More
Cardiovascular

Respiratory

Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Learn More
Respiratory

Specialty

Pulmonary fibrosis is the manifestation of many different conditions that causes scar tissue to build up in the lungs and patients suffering from the condition often experience breathing difficulty. Pulmonary Fibrosis is a common threat across a wide range of interstitial lung diseases (ILDs), including connective tissue diseases (CTDs) and can be a key driver of irreversible harm and early mortality, and requires urgent identification and intervention.1

In 2014, we have forayed into the space of Specialty and have emerged as a leader in the treatment of idiopathic pulmonary fibrosis (IPF) to help patients suffering with their disease.2 Since then, we have gotten approvals globally for other types of lung diseases such as Systemic Sclerosis interstitial lung disease (SSc-ILD) and progressive fibrosis interstitial lung disease (PF-ILD).3,4 To date, We have clinical experience exceeding 80,000 patient-years worldwide.5

  1. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. Eur Resp J. 2018;51:1800692.

  2. Richeldi L, du Bois RM, Raghu G, et al; for the INPULSIS® Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;380(22):2071-2082.

  3. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380:2518-2528.

  4. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727.

  5. Boehringer Ingelheim. Presentations for the July 25, 2019 Meeting of the Arthritis Advisory Committee. 2019 (Accessed Jan 26 2023). Available at: https://www.fda.gov/advisory-committees/july-25-2019-meeting-arthritis-advisory-committee-meeting-announcement-07252019-07252019

Learn More
Specialty_TA

Oncology

Lung cancer remains the most common cause of cancer deaths worldwide for men, and the second most common for women.1 It is estimated that in 2020 there will be 2.3 million new lung cancer cases and 2.0 million resulting deaths worldwide.2 Although patient outcomes are better if the disease is diagnosed in its early stages, the 5-year survival rate for metastatic disease remains less than 5%.3 Non-small cell lung cancer (NSCLC) is the most common tumor type, accounting for approximately 85% of lung cancers.3

At Boehringer Ingelheim, we are providing new hope for patients by taking cancer on. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.

  1. Torre LA, et al. CA Cancer J Clin 2015;65(2):87–108.

  2. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/Pages/burden_sel.aspx (Accessed: 3 July 2017).

  3. Schvartsman G, et al. Ther Adv Med Oncol 2016;8(6):460–73.

Learn More
Oncology